This site is intended for Healthcare professionals only.
×

Strides Shasun gets DCGI nod to manufacture Hepatitis C drug


Strides Shasun gets DCGI nod to manufacture Hepatitis C drug

New Delhi: Drug firm Strides Shasun has received approval from the Drug Controller General of India (DCGI) to produce a generic version of Gilead’s ‘Sovaldi’ used for treatment of Hepatitis C.

The company has received approval for manufacturing a generic version of Sofosbuvir 400 mg, Strides Shasun said in a filing to BSE.

Last year, Strides had entered into a licensing agreement with Gilead Sciences to bring Hepatitis C cure to 91 developing countries.

“The product will continue to be marketed under the brand name Virso in India and overseas,” Strides Shasun said.

................................ Advertisement ................................

Sofosbuvir is the first-in-class polymerase inhibitor to be launched in India for Hepatitis C treatment and represents “a paradigm shift” in the existing Hepatitis C cure, it added.

................................ Advertisement ................................

“The high potency, high barrier to resistance and pan genotype activity make Sofosbuvir a breakthrough drug in Hepatitis C treatment. This drug in combination therapy has shown to have high cure rates of around 90 per cent,” it said.

Globally, it is estimated that 170-185 million people are chronically infected with Hepatitis C virus. In India alone, it is estimated that 12-18 million patients are infected with the disease, which is several fold higher than those with HIV/AIDS.



Source: PTI
0 comment(s) on Strides Shasun gets DCGI nod to manufacture Hepatitis C drug

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted

    Bajaj Doctor Loan